Key Takeaway
Neuralink is one of the most closely watched private companies in the market right now because it sits at the intersection of Elon Musk, brain-computer interfaces, and real clinical progress. The company has kept expanding its patient program through 2024 and 2025, and its latest reported fundraising put a fresh spotlight on just how valuable private investors think it could become.
That combination naturally sends retail investors searching for a way in. The problem is that Neuralink is still private, so the path to ownership is very limited. Here’s what Neuralink does, whether it trades publicly, what an IPO would require, and the realistic ways investors can get exposure today.
What is Neuralink?
Neuralink develops brain-computer interface systems designed to let people control computers using neural signals. Its current work centers on the N1 Implant, the R1 Robot, and the N1 User App, which it is testing in the PRIME Study for people with paralysis. The company says the implant records neural activity through 1,024 electrodes across 64 threads.
Neuralink was founded in 2016 and is headquartered in Fremont, California. It is still in a clinical-stage, pre-revenue phase, and the company has not publicly disclosed revenue or an official employee count on its site. Its stated mission is to restore autonomy for people with unmet medical needs, which is why it has drawn so much attention from both biotech and tech investors.
Is Neuralink publicly traded?
No, Neuralink is currently a privately held company, so there is no Neuralink stock ticker for retail investors to buy on a public exchange. SEC records show Neuralink Corp. filing Form D exempt offerings, not a public registration statement, and there is no public parent company behind it.
